On the 7th June 2016, a technical meeting was held in Paris, hosted by Haute Autorité de Santé (HAS, EUnetHTA Work Package 5 lead). The participants of this meeting not only included all EUnetHTA Joint Action 3 WP leads, but also representatives from industry (pharmaceutical), European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Agency (EMA), HTA agencies and the European Commission.
The issues raised focused on cooperation among all involved parties identifying common grounds on conducting joint scientific assessments. Further importance was placed on identifying barriers and drivers of using the outputs of European collaboration at the national level. General consensus was that JA3 is a crucial element in setting the permanent structure of HTA collaboration.
The outcomes of the meeting indicated that identifying and building trust is very important for joint reports to be adopted at a national level. All participants showed their commitment in moving forth the collaboration, whilst pursuing further interactions to ensure that trust is built and national barriers are identified in order to maintain a sustainable HTA collaboration after 2020 (end of EUnetHTA JA3).
